If I am honest. Not a fan of 6 monthly reporting. Timing of DC's sale is average. Nonetheless, fundamentals remain strong and will hope that any share price weakness is only short term.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025